First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors

NCT03616574 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Solid Tumors
Advanced or Metastatic Colorectal Cancer (mCRC)

Interventions

DRUG: CA102N
DRUG: LONSURF

Sponsor

Holy Stone Healthcare Co., Ltd